Glimric-MV1 Tablet SR is a combination oral antidiabetic medication formulated to improve glycemic control in patients with type 2 diabetes mellitus. It contains Glimepiride 1mg, Metformin 500mg, and Voglibose 0.2mg, each contributing distinct mechanisms to regulate blood glucose levels. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, thereby decreasing insulin resistance. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, attenuating postprandial hyperglycemia. The sustained-release (SR) formulation ensures gradual drug release, promoting improved patient compliance and stable plasma drug concentrations. Glimric-MV1 is indicated as an adjunct to diet and exercise for adults inadequately controlled on monotherapy or dual therapy. It is essential to monitor renal function prior to and during treatment due to the risk of metformin-associated lactic acidosis. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, as well as hypoglycemia, particularly related to glimepiride. This combination therapy should be prescribed under medical supervision with regular monitoring of blood glucose and HbA1c levels to optimize therapeutic outcomes.